





































Meta-analysis and Meta-regression of Survival After Liver
Transplantation for Unresectable Perihilar Cholangiocarcinoma
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Objective: To systematically review studies reporting survival data following
neoadjuvant chemoradiation and orthotopic liver transplantation (NCR-OLT)
for unresectable perihilar cholangiocarcinoma ( pCC).
Background: Despite survival improvements for other cancers, the prognosis
of pCC remains dismal. Since publication of the Mayo protocol in 2000,
increasing numbers of series globally are reporting outcomes after NCR-OLT.
Methods: MEDLINE, EMBASE, Scopus, and Web of Science databases
were searched from January 2000 to February 2019. A meta-analysis of
proportions was conducted, pooling 1, 3-, and 5-year overall survival and
recurrence rates following NCR-OLT across centers. Per protocol and inten-
tion to treat data were interrogated. Meta-regression was used to evaluate PSC
as a confounder affecting survival.
Results: Twenty studies comprising 428 patients were eligible for analysis.
No RCTs were retrieved; the majority of studies were noncomparative cohort
studies. The pooled 1, 3-, and 5-year overall survival rates following OLT
without neoadjuvant therapy were 71.2% (95% CI 62.2%–79.4%), 48.0%
(95% CI 35.0%–60.9%), and 31.6% (95% CI 23.1%–40.7%). These
improved to 82.8% (95% CI 73.0%–90.8%), 65.5% (95% CI 48.7%–
80.5%), and 65.1% (95% CI 55.1%–74.5%) if neoadjuvant chemoradiation
was completed. Pooled recurrence after 3 years was 24.1% (95% CI 17.9%–
30.9%) with neoadjuvant chemoradiation, 51.7% (95% CI 33.8%–69.4%)
without.
Conclusions: In unresectable pCC, NCR-OLT confers long-term survival in
highly selected patients able to complete neoadjuvant chemoradiation fol-
lowed by transplantation. PSC patients appear to have the most favorable
outcomes. A high recurrence rate is of concern when considering extending
national graft selection policy to pCC.
Keywords: cholangiocarcinoma, neoadjuvant chemoradiation, perihilar,
transplantation
(Ann Surg 2021;273:240–250)
T he unanimity of the HPB/transplant community in seekingsubstantial progress toward reversing the dire outcomes of
patients with pCC led to experimentation of transplantation as a
treatment 30 years ago. It was anticipated that transplant would prove
an ideal therapy for unresectable pCC; offering both removal of the
tumor and cure from background parenchymal damage.1 Early
experiences however reported dismal survival rates due to aggressive
early recurrence and the practice was soon abandoned to conserve
grafts for patients with better potential long-term outcomes.2,3 The
publication of the impressive outcomes by the Nebraska group4 and
the Mayo clinic in 20005 and beyond has prompted units around the
world to re-evaluate pCC as an indication for liver transplantation6
and centers have developed protocols to refine patient selection and
introduce neoadjuvant chemoradiation regimes prior to transplant.
These institutional protocol-based experiences have reported recur-
rence-free survival rates that appear comparable or even superior to
resection or transplantation for chronic liver disease or early hepa-
tocellular carcinoma.5,7,8 Today in several centers in the United
States (US) neoadjuvant chemoradiation and liver transplantation
(NCR-OLT) is no longer considered experimental for unresectable
disease but as standard of care9,10 and with an increasing number of
centers in the US and Europe adopting similar protocols and report-
ing favorable outcomes in expanding patient cohorts, evermore
discussion is ensuing globally as regards the safety and utility of
liver transplantation in pCC. The question therefore arises whether
national criteria should be expanded to permit provision of graft
livers to a select group of patients with inoperable pCC. A Model for
End-Stage Liver Disease (MELD) exception for pCC was introduced
in the US in 2009 by the United Network for Organ Sharing/Organ
Procurement and Transplantation Network 9 and in 2006 in the
Eurotransplant MELD countries: Germany, Belgium, and the
Netherlands.11 The rigorous patient selection and arduous neoadju-
vant chemoradiotherapy means that only the fittest patients with
sufficiently favorable disease are suitable for transplantation. How-
ever, variations in selection criteria and neoadjuvant protocols are
likely reflected in the wide range in reported survival rates.7,12,13
Favorable reported survival in intention to treat comparisons has
prompted critics to call for further analysis of the certainty of the
initial diagnosis of pCC in these studies, especially in the context of
patients with dominant PSC strictures. With an established diagnosis
of unresectable pCC, one would expect extremely poor outcomes in
patients not ultimately proceeding to transplantation; however, this
has not always been reflected in survival rates.
Heterogeneity in published reports has made the direct inter-
pretation of clinical outcomes following OLT in pCC highly chal-
lenging. Studies combine data from PSC and non-PSC patients,
perihilar and intrahepatic CC, varying neoadjuvant regimes (doses
and types of chemotherapy, use of radiotherapy) and some include
patients undergoing other major resections such as partial pancrea-
toduodenectomy (PPD). Primary endpoints and lengths of follow-up
differ between studies. Moreover, there continues to be much debate
as to the true correct denominator for comparison in assessing
survival outcomes. Studies have used various groups for comparison,
including those undergoing surgical resection ( adjuvant chemo-
therapy), those undergoing transplantation for hepatocellular
carcinoma (HCC) or chronic liver disease or even palliative
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META-ANALYSIS
chemotherapy. Indeed, palliative chemotherapy remains the most
frequently adopted alternative therapeutic option in patients who
cannot proceed to transplant.
Thus, this systematic review and meta-analysis aims to sys-
tematically evaluate directly comparable survival and oncological
outcome data in patients with unresectable perihilar CC undergoing
OLT in this new era of patient selection and neoadjuvant work-up and
assess whether transplantation represents a safe and effective strategy
in these patients.
METHODS
The protocol for this systematic review was prospectively
registered with the International Prospective Register of Systematic
reviews, PROSPERO (CRD42019127662) and is reported in accor-
dance with the Preferred Reporting Items for Systematic Reviews
and Meta-analysis (PRISMA) and Meta-Analysis of Observational
Studies in Epidemiology (MOOSE) standards (Suppl. Table S1,
http://links.lww.com/SLA/C4).14,15
Study Identification
In collaboration with a senior information specialist, a maxi-
mally sensitive search strategy was developed. A comprehensive
search was conducted of the EMBASE (Ovid), MEDLINE (Ovid),
Scopus, and Web of Science: Core Collection electronic databases
from January 2000 (the year the Mayo Clinic, Rochester, MN
published their first report of a neoadjuvant/OLT protocol) until
February 2019. The following search terms were used: cholangio-
carcinoma, Klatskin tumor, bile duct cancer AND liver transplanta-
tion, liver graft AND survival rate. The reference lists of identified
articles were then manually searched to identify potentially relevant
omitted citations and Google Scholar’s ‘‘Cited By’’ tool was used to
identify other potentially relevant articles that had cited studies
already identified for data extraction. Articles that were not pub-
lished in the English language were not included in this study.
Eligibility/Study Selection
Study selection was performed in 3 stages according to
PRISMA recommendations with 2 reviewers (W.A.C., C.F.) inde-
pendently assessing citations for eligibility. Duplications were
excluded, as were letters, reviews, editorials, supplements, com-
ments, case reports, and case series of fewer than 5 patients. Studies
were excluded if they reported only patients with mixed hepatocel-
lular-cholangiocarcinoma or did not report the primary endpoints of
1, 3-, or 5-year survival rates following OLT. If studies originated
from the same center or included data from the same database, only
the most recent publication or the largest cohort was included in data
synthesis. Database studies incorporating data across centers that
were already primarily reported elsewhere were also excluded. To
reduce the exclusion of gray literature, conference abstracts identi-
fied through the search which met inclusion criteria were included in
the synthesis. Two reviewers selected full-text studies for inclusion in
the review against exclusion and inclusion criteria.
Quality Assessment/Risk of Bias
Three researchers (W.A.C., C.F., R.V.G.) critically appraised
the quality of each study independently using the Newcastle-Ottawa
scale for nonrandomized studies.16 Funnel plots were constructed to
assess publication bias for outcomes reported by a minimum of 8
studies.17
Data Extraction and Outcome Measures
Data were extracted by 1 reviewer (W.A.C.) from each
included study using a data extraction form developed a priori. Data
extracted were study center location, study inclusion period, patient
number and characteristics, comorbidities, etiology of liver disease
(including PSC), anatomical classification of CC, intervention
details in particular type of surgery (OLT or resection), cointerven-
tions (neoadjuvant protocol and/or adjuvant treatment details), pre-
operative assessment of resectability, histological confirmation of
CC on explant, postoperative complications, and length of follow-up.
Primary outcomes were 1, 3-, and 5-year overall survival and the
secondary outcome was recurrence rate at 3 years. Study authors
were approached via email to provide missing data; otherwise these
were treated as ‘‘not reported.’’
Synthesis and Statistical Analysis
A descriptive synthesis was used to summarize study char-
acteristics, patient demographics, and intervention details. The
majority of cohort studies did not report outcome data for a control
group (eg, resection or palliative chemotherapy) and so consequently
meta-analyses of proportions were conducted for data using a
random effects model to calculate pooled 1, 3-, and 5-year overall
survival rates and their confidence intervals using per protocol and
intention to treat data when available.18 Statistical heterogeneity was
assessed using x2 and I2 analyses, with the threshold for heteroge-
neity considered present if the P value was 0.05 or I2 was greater
than 50%. Subgroup analyses were completed for patients who
underwent neoadjuvant therapy and patients who underwent adju-
vant therapy or no therapy. To better understand potential sources of
heterogeneity, random effects meta-regressions were performed for
studies reporting the proportion of patients with PSC. A prespecified
publication bias assessment was performed by means of a funnel
plot. All statistical analyses were performed using MedCalc for
Windows, version 19.0 (MedCalc Software).
RESULTS
Systematic Review
Following the literature search 1717 studies were identified
through the EMBASE, Medline, Scopus, and Web of Science: core
collection databases. Twenty-seven studies were identified from
other sources, namely, through searching the bibliographies of
studies identified for data extraction, and through using Google
Scholar’s ‘‘Cited By’’ tool to identify relevant articles that had cited
studies identified for data extraction. After removal of duplicates, the
titles and abstracts of 1385 studies were screened for inclusion. Of
these 1128 were excluded as not relevant and the full texts of 257
studies were retrieved. Of these 237 did not meet inclusion criteria
(Fig. 1), including 10 studies reporting data from 5 national or
international databases, which included patients already reported
primarily by other studies (Suppl. Table S2, http://links.lww.com/
SLA/C4). This left 20 studies to be included in the quantitative
synthesis that either included or were comprised exclusively of
patients transplanted for unresectable perihilar cholangiocarcinoma
(studies comprised of patients with PSC-related tumors were con-
sidered to be unresectable). The characteristics of these studies are
shown in Table 1. The range of median follow-up was 14 to
89.5 months.
Study Characteristics
No RCTs were retrieved; all studies were observational cohort
studies, case-control studies, or noncomparative series. Study quality
as assessed by the Newcastle Ottawa scale was found to range from
poor to good (range 1–7) (Suppl. Table S3, http://links.lww.com/
SLA/C4). The distributions of effects estimate (survival rates at 1, 3,
and 5 yrs and recurrence rate) plotted against the precision of the
study (standard error) were symmetrical and overall publication bias
was acceptable. Visual interpretation of the funnel plots suggested
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the presence of missing studies reporting enhanced survival rates at
5 years and smaller studies reporting poorer survival outcomes at
3 years (Suppl. Figure S1, http://links.lww.com/SLA/C4).
Patient Population Characteristics
A total of 428 patients from 20 studies were included in the
final meta-analysis with a median age range from 37 to 54 years
(Table 1). By far the largest series was that published by the Mayo
group, comprising 152 patients.19 Thirteen studies declared the sex
distribution of their study population, and of these patients 71% were
male.19–31 Figure 2 shows the geographical distribution of centers
reporting OLT-CR for pCC; 11 studies originated from Europe
(Spain, Germany, Republic of Ireland, UK, Switzerland, Norway),
7 from the United States, 1 from Canada, and 1 from China. There
was variation between studies in terms of inclusion criteria as shown
in Table 1.
Neoadjuvant Protocols
Eleven studies4,19–23,25,30,32–34 reporting 272 patients (63.6%)
underwent a neoadjuvant chemoradiation protocol in >80% of
patients prior to proceeding to transplantation. Two studies reported
data with <20% of the cohort undergoing neoadjuvant treatment and
were therefore not included in this subgroup.27,28 All such studies
used strict patient selection criteria although the full details of these
criteria were not available in the case of Deoliveira et al21 or Solheim
et al33 where only abstracts were available. The most frequent
inclusion criteria were a tumor size of 3 cm, irresectability due
to bilobar involvement, involvement of major hilar structures or the
FIGURE 1. PRISMA flow diagram of search strategy and study selection (PRISMA Preferred Reporting Items for Systematic Reviews
and Meta-analysis).
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presence of parenchymal disease secondary to PSC. All studies with
the exception of Duignan et al22 considered locoregional nodal
involvement to be an exclusion criterion. Six of the 11 studies
included patients with PSC who exhibited a serum CA19–9 of
100 U/mL in the presence of a radiologically malignant stricture
but who did not have positive cytology.4,19,23,25,33,34 Fluorescent in
situ hybridization to detect polysomy on biliary brushings was used
in 1 study.19 Exclusion criteria common to the majority of studies
were resectable disease (except in the context of PSC), any previous
resection attempt, a history of radiotherapy, previous open or trans-
peritoneal biopsy and malignancy in the preceding 5 years (except
squamous cell carcinoma or cervical carcinoma). Three studies
excluded patients with tumor extending beyond the origin of the
cystic duct.25,32,34
The most frequently utilized neoadjuvant regime was that
referred to as the ‘‘Mayo Protocol;’’ 35 which was closely adhered
to in 3 studies reporting 203 patients.19,23,25 The remaining studies
employed a range of variations of this protocol, as detailed in Figure 3.
Following patient selection, the Mayo protocol begins with a course of
External Beam Radiotherapy (EBRT) of 40to 55 Gy given in 30
fractions over 3 to 5 weeks alongside continuous 5-FU infusion.
Departures from this regime included the substitution of 5-FU for
oral capecitabine,32 the use of EBRT without concomitant chemother-
apy,30 the use of Stereotactic Body Radiotherapy (without chemother-
apy),34 or no EBRT at all.4 No studies of these 11 presented data using
neoadjuvant chemotherapy alone without radiation.
Patients would then go on to receive brachytherapy delivered
via percutaneously or endoscopically placed wires delivering 8 to 60
Gy Iridium-192 with or without concomitant 5-FU or capecita-
bine,4,19,23,25,33 with or without an external boost of radiotherapy,25
brachytherapy without chemotherapy4,28,30 or no brachytherapy at
all.21,32,34 In 1 study brachytherapy was used prior to EBRT.22
Patients then underwent staging laparoscopy or laparotomy. This
was performed on completion of the neoadjuvant regime in 1 center22
but more commonly at the time of deceased donor transplant or the
day prior to living donor transplantation. There was variation in
practice in terms of nodal sampling, with 5 of the 11 neoadjuvant
studies sampling hepatoduodenal and hepatic artery lymph nodes at
laparoscopy.4,19,22,23,32 Almost all studies continued chemotherapy
(either 5-FU or capecitabine) until the time of transplant (held
perioperatively).4,19,22,23,25,30,34 The protocol published by Loveday
et al32 substituted 5-FU/capecitabine for gemcitabine and cisplatin.
Intraoperative Practices
The consistency between studies in the reporting of intraop-
erative practices was poor. There was variation in surgical technique
and use of adjunctive procedures. Two studies exclusively reported
data on patients undergoing OLT after living donation20,36 and 5
studies included patients transplanted after either living or cadaveric
donation.19,21,25,28,32 In 4 of these 5 studies patients underwent
treatment with a neoadjuvant protocol prior to living donor trans-
plantation.19,21,25,32 Six studies included patients undergoing con-
current partial PPD22,26,29,34,36 and 2 of these studies were comprised
exclusively of patients undergoing OLT-PPD from the outset.29,30
The use of extended bile duct resection/en-bloc resection of the
hepatoduodenal ligament and reconstruction with roux-en-Y hepa-
ticojejunostomy was widespread but many studies did not declare
their operative technique. Regional lymphadenectomy was specifi-
cally cited as a routine procedure in 4 studies.4,26,29,34
Primary Outcomes: 1, 3, 5-year Survival
Survival for all patients after OLT for pCC at 1-year was
reported by 18 out of 20 studies (265 patients),20,22–34,36–39 3-year
survival by 13 studies (240 patients),4,22–31,36–39 and 5-year survival
by 10 studies (309 patients).4,19,23,24,26–30,38 Meta-analysis showed
that pooled survival was 76.9% at 1 year (95% CI ¼ 69.5%–83.5%;
FIGURE 2. Geographical distribution of studies included in quantitative synthesis.
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I2 43.9%), 55.3% at 3 years (95% CI¼ 43.7%–66.5%; I268.4%), and
44.9% at 5 years (95% CI ¼ 31.4%–58.8%; I2 78.6%). In patients
who underwent a neoadjuvant protocol (NCR-OLT) for pCC across
11 studies (272 patients), survival at 1 year was reported by 9 studies
(109 patients),4,20,22,23,25,30,32–34 survival at 3 years by 5 studies (89
patients),4,21,23,25,30 and at 5 years by 4 studies (210 patients).4,19,23,30
Meta-analysis of these data showed that pooled survival at 1 year was
82.8% (95% CI¼ 73.0% –90.8%; I2 33.0%), 65.5% at 3 years (95%
CI ¼ 48.7%–80.5%; I2 58.7%), and 65.1% at 5 years (95% CI ¼
55.1% –74.5%; I2 31.2%) (Fig. 4A).
As a large proportion of the survival outcomes were made up
of patients reported by the Mayo Clinic (152 out of 210 patients), 5-
year survival of patients from the Mayo Clinic was compared to
pooled survival from other, non-Mayo centres (Supplementary
Figure S2A, http://links.lww.com/SLA/C4).4,23,30 The 5-year sur-
vival of patients undergoing a neoadjuvant protocol followed by
transplantation (NCR-OLT) at the Mayo Clinic was not significantly
different to that of patients at non-Mayo centres (Mayo Clinic 69.0%,
95% CI 61.0%–76.2% vs non-Mayo 60.6%, 95% CI 42.3%–77.4%,
x2 ¼ 1.2; P ¼ 0.27).
FIGURE 3. Patient workup and neoadjuvant protocols reported in the final 20 studies included in the meta-analysis.
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In patients who did not undergo neoadjuvant protocol (9
studies; 156 patients), survival at 1 year was reported by 9 studies
(156 patients),24,26–29,31,36–39 at 3 years by 8 studies (151
patients),24,26–29,31,37,38 and at 5 years by 6 studies (99
patients).24,26,27,29,38 Meta-analysis showed that pooled survival at
1 year without neoadjuvant therapy was 71.2% (95% CI 62.2% –
79.4%; I2 28.5%), 48.0% at 3 years (95% CI 35.0%–60.9%;
I258.9%), and 31.6% at 5 years (95% CI ¼ 23.1% –40.7%; I2
0.0%) (Fig. 4B).
Secondary Outcomes: Recurrence Rate
Disease recurrence was analyzed in studies which followed
patients for 36 months (8 studies; 262 patients).4,19,20,22,23,27,29,30
Meta-analysis showed that the pooled recurrence rate overall at
3 years was 29.4% (95% CI ¼ 20.1%–39.7%). In patients who
underwent neoadjuvant therapy (NCR-OLT) the recurrence rate was
24.1% (95% CI ¼ 17.9% –30.9%; I2 11.1%) (6 studies and 235
patients).4,19,20,22,23,30 In patients who did not undergo neoadjuvant
therapy the recurrence rate was 51.7% (95% CI¼ 33.8% –69.4%; I2
0.0%) (2 studies; 27 patients)27,29 (Fig. 5).
To assess any potential difference in recurrence rates between
Mayo and non-Mayo centers, recurrence at 3 years was compared
between those reported by Lehrke et al (152 patients) and pooled
recurrence from non-Mayo centers (83 patients) (Supplementary
Figure S2B, http://links.lww.com/SLA/C4).4,20,22,23,30 No significant
difference was observed in recurrence at 3 years between the Mayo
FIGURE 4. Forest plots of 20 cohort studies reporting survival outcomes following NCR-OLT for pCC with (A) and without
neoadjuvant chemoradiation (B). Random effects modeling of pooled survival rates at 1, 3, and 5-yrs was used for the meta-analysis
of proportions with 95% confidence intervals.
FIGURE 5. Forest plots of recurrence rates at 36 mo of follow-up with (left) and without (right) neoadjuvant treatment and OLT for
unresectable pCC. Random effects modeling of pooled recurrence rates with 95% confidence intervals was used for the meta-
analysis of proportions.
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Clinic (23.0%, 95% CI 16.6%–30.5%) and non-Mayo centers
(24.6%, 95% CI 14.2%–36.7%) x2 ¼ 0.03; P ¼ 0.85.
Preoperative Diagnosis and Complete Pathological
Response Rate
Just 4 out of 20 studies reported the number of patients who
had a pathological diagnosis of cholangiocarcinoma confirmed
histologically prior to transplantation (confirmed in 40 out of 42
patients; 9% of all patients included in this analysis).4,20,22,30 This
was defined by these studies as either proven adenocarcinoma on
biopsy or malignant or suspicious brushings. Other studies including
the Mayo series included patients with a clinical diagnosis including
those with a radiologically malignant stricture and a CA19–9 of
>100U/mL.19,23,25,32
Of the 9 studies that did not use a neoadjuvant protocol prior to
transplant, all 9 reported the proportion of patients with a patholog-
ically confirmed diagnosis of pCC (histological examination of the
explanted liver) and this was confirmed in 142 out of 145 explants
(98%). Of the 11 studies presenting neoadjuvant transplant programs, 9
studies (256 patients) presented data on pathological diagnosis in the
explanted liver.4,19,20,22,23,25,30,32,34 Of these 255 patients undergoing
neoadjuvant protocols (1 patient in the study from Axelrod et al did not
undergo neoadjuvant treatment), 126 (49.6%) had no evidence of
adenocarcinoma on histopathological examination. This does not
include the 5 transplanted patients in the study by Ethun et al23 which
incorporated data from 10 US institutions, who were given a diagnosis
other than pCC after pathological examination of the explanted liver
and who were excluded from the paper’s final survival analysis.
Intention to Treat Versus Per Protocol Survival
One aim of this study was to analyze per protocol and
intention to treat data to differentiate survival rates between patients
initially assessed compared with those who completed the NCR-OLT
regime. Ultimately this was not possible as only 3 studies presented
survival data for both groups of patients.20,32,34 Furthermore, the
definition of the patient groups undergoing initial assessment varied
between studies, for example some studies included patients with
resectable disease, some included patients with cholangiocarcinoma
not located at the hilum etc. Evaluation of the drop-out rate between
the time of patient assessment to administration of neoadjuvant
chemoradiation and OLT was hampered by incomplete data and
heterogeneous data presentation between studies. Of the 11 studies
reporting outcomes of patients receiving NCR-OLT, only 5 studies
presented the numbers of patients initially assessed alongside the
number of patients successfully transplanted.22,23,30,32,34 One of
these studies was comprised of patients with asymptomatic PSC
undergoing endoscopic surveillance and therefore was excluded.30
Of the remaining 4 studies, the drop-out rate ranged from 25.9% to
86.1%. Six studies presented data comparing the number of patients
commencing the neoadjuvant protocol to those successfully trans-
planted.4,23,25,30,32,34 Here, the drop-out rate ranged from 0.0% to
66.7%. The most frequently cited indications for drop out were
disease progression (n ¼ 32, 41%), diagnosis of extrahepatic disease
(n ¼ 19, 24%) (including 5 patients (6.7%) with positive surgical
staging laparoscopy and 2 patients with involved lymph nodes at
EUS (2.7%)), death prior to transplantation (n ¼ 8, 10.7%), patient
refusal (n ¼ 3, 4%), diagnosis of metastatic disease (n ¼ 1, 1.3%),
and alteration of the surgical plan to resection (n ¼ 1, 1.3%).
Morbidity
Morbidity was variably reported by studies. Adequate reporting
of morbidity was predefined as inclusion of the incidence of severe
complications (Clavien-Dindo Grades III and IV) and the rate of
retransplantation. This standard was met by 3 out of 20 studies which
reported morbidity rates of 44% to 100%.4,28,31 Several studies listed
adverse events without stating the number of patients to whom these
occurred. Only 1 study differentiated between morbidities arising
pretransplant as a result of the neoadjuvant regime versus post-OLT
complications.4 Eight studies (105 patients) reported a retransplanta-
tion rate and this ranged from 0% to 40%.4,20,22,26,28,30,31,34
Primary Sclerosing Cholangitis
Thirteen of the 20 studies reported the proportion of patients
with PSC undergoing transplantation.19,20,23,24,26,28–31,33,36–38 Of
these 365 patients, 180 (49.3%) had a background of PSC. Survival
outcomes were not reported for patients with PSC as a specific
subgroup by almost any study and therefore univariate meta-regres-
sions were undertaken to explore potential heterogeneity between
studies arising due to PSC as a potential confounder and assess
whether the proportion of PSC patients per study affected survival in
studies where 3 and 5-year survival outcomes had been declared
(Fig. 6). Ten studies reporting 3-year survival data4,22–24,28–31,37,38
FIGURE 6. Random effects univariate meta-regression of survival at 3 yrs following transplantation for pCC (with and without
neoadjuvant chemoradiation) versus the proportion of patients with PSC in each study (left graph) and at 5 yrs after transplantation
for pCC (with and without neoadjuvant chemoradiation) (right graph) (scatter diagrams are log weighed). Each dot represents an
individual study, the solid line represents the regression prediction, and the dotted lines the 95% confidence intervals.
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and 9 studies reporting 5-year survival data9,19,23,24,28–30,37,38
declared the number of patients with PSC within the cohort. The
association between number of patients with PSC and survival was
not statistically significant for 3-year survival (adjusted R2¼ 0.48, P
¼ 0.172); however at 5 years there was a positive correlation between
the proportion of patients with PSC in the study and survival
(adjusted R2 ¼ 0.82, P ¼ 0.007). Insufficient studies were available
(n¼ 5) to assess whether the proportion of patients with PSC affected
disease recurrence post OLT/NCR-OLT for pCC.
Other Factors
Seven out of 20 studies included patients undergoing living
donation liver transplantation (LDLT)19–21,25,28,32,36 including 2
studies comprised solely of patients receiving grafts from living
donors.20,36 The rate of living donation ranged from 43.8% to 100%
(comprising a total of 27 patients; 6.3% of all patients). Two studies
did not report the number of patients undergoing living donor liver
transplant19,25 and 5 studies did not distinguish outcomes between
living and deceased donations, leaving reported outcomes for just 12
patients (2.8% of the overall pooled cohort). Five of the 7 studies
employed neoadjuvant protocols19–21,25,32 and donor hepatectomy
was timed to immediately follow recipient exploration to exclude
extrahepatic disease.
Six out of 20 studies included patients who underwent partial
pancreatoduodenectomy alongside liver transplant (PPD-
OLT).22,26,29,30,34,36 The rate of PPD-OLT ranged from 5.6% to
100% in these studies, comprising a total of 32 patients (7.5% of
all patients). In some cases, PPD-OLT was planned from the outset of
surgery, in others an intraoperative decision was taken to proceed to
PPD-OLT due to positive frozen sections at the specimen margin.
DISCUSSION
This meta-analysis has shown that the pooled 5-year survival
for patients undergoing liver transplant for unresectable pCC exceeds
the 50% 5-year survival threshold broadly accepted by many liver
transplant units if a neoadjuvant regime is completed (65.1%, 95% CI
55.1% –74.5%) but does not meet this standard if the patient
proceeds directly to transplantation (31.6%, 95% CI 23.1%–
40.7%). These pooled survival data for NCR-OLT certainly compare
favorably to the outcomes of patients undergoing resection, where 5-
survival rates of 35% to 45% are widely cited.40–42 A previous meta-
analysis of 5 studies comparing OLT to resection in operable pCC has
demonstrated a trend toward improved survival for OLT at 1, 3, and
5 years (78% vs 72.5%, 55.5% vs 44%, and 46% vs 31%), although
this did not achieve statistical significance (mortality odds ratio of
0.72 [0.30–1.69] in favor of OLT at 5 yrs).43 This was echoed by a
further meta-analysis of patients with nondisseminated nonresectable
tumors undergoing NCR-OLT or resection, where noninferior sur-
vival was observed in the NCR-OLT group, although it must be noted
that very few patients undergoing resection underwent any sort of
neoadjuvant therapy.44 Awell-powered randomized controlled trial is
required for the specific context of non-PSC related perihilar CC
where there exists the alternative surgical option of resection, and the
TRANSPHIL trial (NCT02232932) which has a planned completion
date of 2021, aims to address this question.45 Currently, the evidence
supporting transplantation in this situation remains uncertain, espe-
cially as the rate of positive margins or inoperability at exploration is
high in these patients.
In terms of tumor recurrence our analysis demonstrates that
the use of neoadjuvant chemoradiation halves the risk of recurrence
at 3 years (51.7% vs 24.1%). As it is established that recurrence is
responsible for the majority of deaths following transplantation for
cholangiocarcinoma19,26 these data in their current form would
support the case made most strongly by US centers that the use
of transplantation for pCC without neoadjuvant chemoradiation
should no longer be supported. Currently, Eurotransplant does not
consider neoadjuvant therapy a prerequisite for graft allocation in
cholangiocarcinoma,46 and further data on recurrence in the absence
of neoadjuvant therapy are required to make a decisive conclusion as
regards this question.
In a field where the risks of surgery are high and prognosis
poor, it was feared that significant publication bias might be encoun-
tered in favor of studies with positive outcomes; however, our
analysis suggests that this is not true in terms of survival reporting.
Insufficient studies reported data on disease recurrence to make a
valid assessment for this secondary outcome. It has not been possible
to accurately evaluate the role of selection bias on survival outcomes
after NCR-OLT in this analysis as true intention to treat data was
rarely available. Insufficient studies reported the number of patients
initially assessed and it was frequently difficult to ascertain the nature
of the group. In some publications this cohort included patients with
hilar and intrahepatic cholangiocarcinoma, those with both unre-
sectable and resectable disease, patients unfit for surgery, patients
with extrahepatic spread, patients whose disease progressed etc.
Furthermore, the outcomes of patients not enrolled on the NCR-
OLT protocol and what treatment they subsequently received were
incompletely reported. In a previous single-institution observational
study, 1, 3, and 5-year survival rates of 92%, 82%, and 82% for 38
patients undergoing transplantation were reported compared with
rates of 79%, 61%, and 58% for all 71 patients initially enrolled in the
protocol.7 This drop-out rate of 46% contrasts with a rate of 25%
reported in a study of 12 US centers, where drop-out was defined as
positive staging, tumor metastases, death, or withdrawal at any time
before transplantation.47 The analysis of such variance in patient
selection is critical to understanding the reasons that non-Mayo
centers frequently report inferior outcomes due to higher in-hospital
mortality and needs to be characterized in greater detail before
widespread protocol adoption can occur. In this relatively rare
disease such heterogeneity has hampered the interpretation of out-
comes and has arguably impeded progress toward clear identification
of the group of patients who may significantly benefit from the NCR-
OLT regime and global adoption of the protocol. To this end,
consensus should be sought toward agreeing a standardized, mini-
mum dataset for all patients evaluated and enrolled on NCR-OLT
programs. Herein, we suggest a proposed collection form for such a
dataset, based on parameters that were required in the preparation
and analysis of this study, sufficient for intention-to-treat evaluation
of the effects of patient selection and neoadjuvant protocols on
outcomes (Supplementary Table S4, http://links.lww.com/SLA/C4).
The cumulative publication of results by the Mayo Clinic
meant that for this meta-analysis the most recent and largest of their
series citing the primary outcome of this review was selected for
inclusion.19 Individual studies have themselves highlighted how
variability in surgical work-up and the NCR-OLT protocol is likely
to affect survival; positive lymph nodes identified at EUS, the R0 rate,
and the presence of residual tumor in the explanted liver have been
previously identified as the factors most predictive for disease
recurrence.19,34 This review identified wide variation in the diagnos-
tic and neoadjuvant pathways of these patients and as the use of
chemoradiation appears critical for achieving the broadly accepted
50% 5-year survival threshold for transplantation, improved consen-
sus and uniformity across centers is again required. Most crucially in
our view, agreement as to the necessity of histopathological diagnosis
prior to NCR-OLT should be sought. Mayo studies and others include
patients onto NCR-OLT protocols with a cancer antigen 19–9 level
of >100 U/mL in the context of a radiologically malignant stric-
ture.8,48 Whilst this may represent a clinical scenario that might
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frequently win clinical consensus to the individual’s requirement for
transplantation, it must be conceded that this is unlikely to yield a
100% pathological diagnosis of pCC and might confuse subsequent
comparison in oncological outcomes to studies not including such
patients.35,48 Indeed, some argue that in the absence of histological
diagnosis prior to NCR-OLT, the true complete pathological
response rate can never be determined. A previous study has shown
that 5-year survival is significantly inferior for patients with PSC who
have a confirmed pathological diagnosis of cholangiocarcinoma
prior to transplant49 and although there was no statistical difference
found between the rate of confirmed pCC in explants or recurrent
cancer in patients with or without a confirmed pathological diagno-
sis, the number of patients with recurrent cancer was relatively small.
The outcomes of such patients therefore need to be examined and
analyzed separately across centers to establish the true benefit
conferred by neoadjuvant chemoradiation which may indeed even
be under-represented in our study where only 9% of all patients had a
histologically proven diagnosis. It should be noted that this is
significantly less than other previously published single-institution
studies49 and is likely a result of histological diagnosis not being the
primary end-point of the systematic search criteria used here. This
serves to further compound the need for a consensus minimum
reporting standard for data in this field.
In our review the correlation between a diagnosis of PSC and
enhanced survival was not statistically significant at 3 years but
exceeded this threshold at 5 years (adjusted R2 ¼ 0.82, P ¼ 0.007).
As there were insufficient studies to separate patients undergoing
neoadjuvant therapy or proceeding directly to transplantation with
and without PSC, it remains unknown whether there were propor-
tionally more patients with PSC undergoing NCR-OLT regimes in
this pooled cohort. It is therefore plausible that this might confound
this observation of enhanced survival although it should be noted that
the proportion of patients in this PSC subgroup (49.3%) was signifi-
cantly less than that reported by other multicenter analyses.23,47
Proponents of LDLT for pCC hypothesize that reduced wait-
ing list time will result in reduced disease progression and better
outcomes.28 The number of patients in this pooled cohort with
reported outcomes for LDLT was too small to assess whether LDLT
in the context of pCC may offer survival benefit over cadaveric
donation. As for HCC, MELD exception points are currently allo-
cated to patients in Europe meeting selection criteria on the waiting
list for pCC. European studies have shown therefore that few patients
with pCC proceed to transplantation.28,37
Similarly, the number of patients undergoing PPD-OLT rep-
resented a small proportion of the entire cohort and therefore
conclusions on the role of extended bile duct resection and partial
pancreatoduodenectomy cannot be drawn. The largest series of PPD-
OLT in this review reported 1, 3, and 5-year survival rates of 63%,
38%, and 38%. Despite no neoadjuvant regime used in this study, a
94% morbidity rate was reported (15 out of 16 patients), with 2
patients requiring total pancreatectomy soon after transplantation for
pancreatic leakage. The oncological benefits of PPD-OLT, particu-
larly following neoadjuvant therapy, remain unresolved.
CONCLUSIONS
This systematic review and meta-analysis conclude that long-
term survival is possible in patients undergoing NCR-OLT for
unresectable pCC with the best prognosis observed in patients with
PSC. Acceptable survival rates are not achieved if a neoadjuvant
regime is not completed. The quality of data reporting in this field is
poor and is hampering interpretation of outcomes. A minimum
expected dataset should be established for all future studies examin-
ing the use of transplantation in cholangiocarcinoma.
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